Neutralization Epitopes of the F Glycoprotein of Respiratory Syncytial Virus: Effect of Mutation Upon Fusion Function

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1989 Jul 1

PMID 2470922

Citations 139

Authors

J A Beeler

K Van Wyke Coelingh

Affiliations

Soon will be listed here.

Abstract

Eighteen neutralizing monoclonal antibodies (MAbs) specific for the fusion glycoprotein of the A2 strain of respiratory syncytial virus (RSV) were used to construct a detailed topological and operational map of epitopes involved in neutralization and fusion. Competitive binding assays identified three nonoverlapping antigenic sites (A, B, and C) and one bridge site (AB). Thirteen MAb-resistant mutants (MARMs) were selected, and the neutralization patterns of the MAbs with either MARMs or RSV clinical strains identified a minimum of 16 epitopes. MARMs selected with antibodies to six of the site A and AB epitopes displayed a small-plaque phenotype, which is consistent with an alteration in a biologically active region of the F molecule. Analysis of MARMs also indicated that these neutralization epitopes occupy topographically distinct but conformationally interdependent regions with unique biological and immunological properties. Antigenic variation in F epitopes was examined by using 23 clinical isolates (18 subgroup A and 5 subgroup B) in cross-neutralization assays with the 18 anti-F MAbs. This analysis identified constant, variable, and hypervariable regions on the molecule and indicated that antigenic variation in the neutralization epitopes of the RSV F glycoprotein is the result of a noncumulative genetic heterogeneity. Of the 16 eptiopes, 8 were conserved on all or all but 1 of 23 subgroup A or subgroup B clinical isolates.

Citing Articles

MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies.

Abiona O, Wang N, Leist S, Schafer A, Cockrell A, Wang L iScience. 2025; 28(2):111632.

PMID: 39898019 PMC: 11783452. DOI: 10.1016/j.isci.2024.111632.

DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection.

Yang Y, Wang R, Guo F, Zhao T, Lei Y, Yang Q NPJ Vaccines. 2024; 9(1):258.

PMID: 39741146 PMC: 11688450. DOI: 10.1038/s41541-024-01059-9.

From setbacks to success: lessons from the journey of RSV vaccine development.

Cnossen V, van Leeuwen R, Mazur N, Vernhes C, Ten Voorde W, Burggraaf J Ther Adv Vaccines Immunother. 2024; 12:25151355241308305.

PMID: 39711948 PMC: 11660060. DOI: 10.1177/25151355241308305.

Mutations in the F protein of the live-attenuated respiratory syncytial virus vaccine candidate ΔNS2/Δ1313/I1314L increase the stability of infectivity and content of prefusion F protein.

Alamares-Sapuay J, Kishko M, Lai C, Parrington M, Delagrave S, Herbert R PLoS One. 2024; 19(4):e0301773.

PMID: 38593167 PMC: 11003679. DOI: 10.1371/journal.pone.0301773.

All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?.

Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P Vaccines (Basel). 2024; 12(1).

PMID: 38250910 PMC: 10819635. DOI: 10.3390/vaccines12010097.

References

Olmsted R, Elango N, Prince G, Murphy B, Johnson P, Moss B . Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A. 1986; 83(19):7462-6. PMC: 386738. DOI: 10.1073/pnas.83.19.7462. View

Wang M, Skehel J, Wiley D . Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera. J Virol. 1986; 57(1):124-8. PMC: 252706. DOI: 10.1128/JVI.57.1.124-128.1986. View

Walsh E, Cote P, Fernie B, Schlesinger J, Brandriss M . Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol. 1986; 67 ( Pt 3):505-13. DOI: 10.1099/0022-1317-67-3-505. View

Gimenez H, Hardman N, Keir H, Cash P . Antigenic variation between human respiratory syncytial virus isolates. J Gen Virol. 1986; 67 ( Pt 5):863-70. DOI: 10.1099/0022-1317-67-5-863. View

Abenes G, Kida H, Yanagawa R . Antigenic mapping and functional analysis of the F protein of Newcastle disease virus using monoclonal antibodies. Arch Virol. 1986; 90(1-2):97-110. DOI: 10.1007/BF01314148. View

Akerlind B, Norrby E . Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden. J Med Virol. 1986; 19(3):241-7. DOI: 10.1002/jmv.1890190306. View

Fenner M, Binz H . Monoclonal antibodies specific for Sendai virus. I. Production and characterization of monoclonal antibodies. Scand J Immunol. 1986; 24(3):335-40. DOI: 10.1111/j.1365-3083.1986.tb02102.x. View

Hsu M, Scheid A, Choppin P . Protease activation mutants of Sendai virus: sequence analysis of the mRNA of the fusion protein (F) gene and direct identification of the cleavage-activation site. Virology. 1987; 156(1):84-90. DOI: 10.1016/0042-6822(87)90438-7. View

Portner A, Scroggs R, Naeve C . The fusion glycoprotein of Sendai virus: sequence analysis of an epitope involved in fusion and virus neutralization. Virology. 1987; 157(2):556-9. DOI: 10.1016/0042-6822(87)90301-1. View

10.

Routledge E, Willcocks M, Morgan L, Samson A, Scott R, Toms G . Heterogeneity of the respiratory syncytial virus 22K protein revealed by Western blotting with monoclonal antibodies. J Gen Virol. 1987; 68 ( Pt 4):1209-15. DOI: 10.1099/0022-1317-68-4-1209. View

11.

van Wyke Coelingh K, WINTER C, Jorgensen E, Murphy B . Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase.... J Virol. 1987; 61(5):1473-7. PMC: 254125. DOI: 10.1128/JVI.61.5.1473-1477.1987. View

12.

Portner A, Scroggs R, Metzger D . Distinct functions of antigenic sites of the HN glycoprotein of Sendai virus. Virology. 1987; 158(1):61-8. DOI: 10.1016/0042-6822(87)90238-8. View

13.

Pothier P, Ghim S, Bour T, Gouyon J, DAUVERGNE M . Antigenic variations of respiratory syncytial virus in recurrent infections. Eur J Clin Microbiol. 1987; 6(2):212. DOI: 10.1007/BF02018219. View

14.

Walsh E, Brandriss M, Schlesinger J . Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol. 1987; 68 ( Pt 8):2169-76. DOI: 10.1099/0022-1317-68-8-2169. View

15.

Johnson P, Spriggs M, Olmsted R, Collins P . The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A. 1987; 84(16):5625-9. PMC: 298915. DOI: 10.1073/pnas.84.16.5625. View

16.

MUFSON M, Belshe R, Orvell C, Norrby E . Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol. 1987; 25(8):1535-9. PMC: 269264. DOI: 10.1128/jcm.25.8.1535-1539.1987. View

17.

Storch G, Park C . Monoclonal antibodies demonstrate heterogeneity in the G glycoprotein of prototype strains and clinical isolates of respiratory syncytial virus. J Med Virol. 1987; 22(4):345-56. DOI: 10.1002/jmv.1890220407. View

18.

Johnson Jr P, Olmsted R, Prince G, Murphy B, Alling D, Walsh E . Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol. 1987; 61(10):3163-6. PMC: 255893. DOI: 10.1128/JVI.61.10.3163-3166.1987. View

19.

Trudel M, Nadon F, Seguin C, Dionne G, Lacroix M . Identification of a synthetic peptide as part of a major neutralization epitope of respiratory syncytial virus. J Gen Virol. 1987; 68 ( Pt 9):2273-80. DOI: 10.1099/0022-1317-68-9-2273. View

20.

Smith D, Inglis S . The mutation rate and variability of eukaryotic viruses: an analytical review. J Gen Virol. 1987; 68 ( Pt 11):2729-40. DOI: 10.1099/0022-1317-68-11-2729. View